Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

The Malignant Neuroleptic Syndrome (MNS) at the bipolar affective disorder patient treated with olanzapine

Malin D.I., Tsukarzi E.E., Potapov I.V., Manasevich A.G., Maslennikov N.V.
Federal State Budgetary Institution “Federal Medical Research Center of Psychiatry and Narcology of V. P. Serbsky Ministry of Health of Russian Federation”

Резюме.Article is devoted by the to analysis of a clinical case of the bipolar affective disorder patient treated with olanzapinе and developed MNS. The algorithm of diagnostics and differential diagnostics and approaches to therapy are described, the efficiency of use of EST is shown. Also describes the state of the problems with the analysis of modern publications.

References: 
  • 1. Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv. – M.: Vuzovskaya kniga, 2000. − 207 s.
  • 2. Tsygankov B.D. Kliniko-patogeneticheskie zakonomernosti razvitiya febril'nykh pristupov shizofrenii i sistema ikh terapii. − M.: Norma, 1997. − 232 c.
  • 3. Caroff S.N. The neuroleptic malignant syndrome // J Clin Psychiat. − 1980. − Vol. 41, No. 3. − P. 1−26.
  • 4. Levenson J.L. Neuroleptic malignant syndrome // Amer J Psychiat. − 1985. − Vol. 142, No. 10. − P. 1137−1145.
  • 5. Moscovich M., Novak F., Fernandes A. et al. Neuroleptic malignant syndrome // Arq Neuropsiquiatr. − 2011. − Vol. 69, No. 5. − P. 751−755.
  • 6. Reulbach U., Dutsch C., Biermann T. et al. Managing an effective treatment for neuroleptic malignant syndrome // Critical Care. − 2007. − Vol. 11. − P. 4−10.
  • 7. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome // Am J Psychiatry. − 2007. − Vol. 164. − P. 870–876.
  • 8. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome // Psychopharmacol Bull. − 1988. − Vol. 24. − P. 25–29.
  • 9. Keck P.E., Pope H.G., McElroy S.L. Declining Frequency of Neuroleptic Malignant Syndrome in a Hospital Population // Amer J Psychiat. − 1991. − Vol. 148, No. 7. − P. 880−882.
  • 10. Spivak B. Malin D., Kozirev V. et al. Frequensy of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow // Eur Psychiatry. − 2000. – Vol. 15. − P. 330−333.
  • 11. Keck P.E, Pope H.G ., Cohen B.M., McElroy SL, Nierenberg A.A. Risk factors for neuroleptic malignant syndrome. A case-control study // Arch Gen Psychiatry. − 1989. − Vol. 46. − P. 914−918.
  • 12. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya pomoshch' v psikhiatrii // Neotlozhnaya pomoshch' v meditsinskoi praktike / pod red. A.B.Vertkina, B.S. Briskina. − M.: Litera, 2007. − S. 57−93.
  • 13. Norgard N.B., Stark J.E. Olanzapine-associated neuroleptic malignant syndrome // Pharmacotherapy. − 2006. − Vol. 26. − P. 1180−1182.
  • 14. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina − klinicheskoi praktike) / pod red. S.N. Mosolova. − M.: Politicheskaya mysl', 2012. − C. 810−829.
  • 15. Karlson A., Lekrub'e I. Dofaminovaya teoriya patogeneza shizofrenii: rukovodstvo dlya vrachei / pod red. S.N. Mosolova.− London, 2004.
  • 16. Spivak B. Malin D., Vered Y. et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignaut syndrome // Acta Psychitr Scand. − 2000. − V. 101. − P. 226−230.
  • 17. Avrutskii G.Ya. Raiskii V. A. Tsygankov B. D. Klinika i techenie zlokachestvennogo neirolepticheskogo sindroma (ostroi febril'noi neirolepticheskoi entsefalopatii) // Zhurn. nevropatol. i psikhiatr. − 1987. − Vyp. 9. − S. 1391−1396.
  • 18. Chekhonin V.P., Morozov G.V., Morkovkin V.M., Kekelidze Z.I. Immunokhimicheskoe izuchenie pronitsaemosti gematoentsefalicheskogo bar'era pri kriticheskikh sostoyaniyakh, obuslovlennykh febril'noi shizofreniei i ostrymi alkogol'nymi entsefalopatiyami // Mat. 8-go s"ezda nevropat. i psikhiatr. − M., 1988. − T. 3. − S. 132−134.
  • 19. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya terapiya v psikhiatrii // Meditsina kriticheskikh sostoyanii. − 2004. − № 6. − S. 36−41.
  • 20. Kekelidze Z.I. Chekhonin V. P. Kriticheskie sostoyaniya v psikhiatrii. − M.: GNTsSSP im. V.P. Serbskogo, 1997. − 362 s.
  • 21. Mann S.C., Auriacombe M., Macfadden W. et al. Lethal catatonia: clinical aspects and therapeutic intervention. A review of the literature [in French] // Ence´phale. − 2001. − Vol. 27. − P. 213−216.
  • 22. Luchini F., Lattanzi L., Bartolommei N. et al. Catatonia and neuroleptic malignant syndrome: Two disorders of the same spectrum? Four case reports // J Nerv Ment Dis. − 2013. − Vol. 1. − P. 36–42.
  • 23. Romasenko V.A. Gipertoksicheskaya shizofreniya. − M.: Meditsina, 1967. − 240 s.
  • 24. Tiganov A.S. Febril'naya shizofreniya: klinika, patogenez, lechenie. − M.: Meditsina, 1982. − 128 s.
  • 25. Stauder K.N. Die todliche Katatonie // Arch Psychiat Nervenkr. − 1934. − Bd. 102. − S. 614−634.
  • 26. Mosolov S.N., Tsukarzi E.E., Alfimov P.V. Algoritmy biologicheskoi terapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. − 2014. − № 1. − S. 27−36.
  • 27. Malin D.I. Zlokachestvennyi neirolepticheskii sindrom: diagnostika i terapiya // Sovremennaya terapiya psikhicheskikh rasstroistv. − 2016. − № 2. − S. 2−8.
  • 28. Malin D.I. Ryvkin P.V. Klinicheskie rekomendatsii po rasstroistvam soznaniya u bol'nykh s kriticheskimi sostoyaniyami // Sovremennaya terapiya psikhicheskikh rasstroistv. − 2016. − № 1. − S. 28−36.
  • 29. Ghaziuddin N., Alkhouri I., Champine D. et.al. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment // J ECT. − 2002. − Vol. 18, No. 2. − P. 95−98.
  • 30. Patel A.L., Shaikh W.A., Khobragade A.K. Et al. Electroconvulsive Therapy in Drug Resistant Neuroleptic Malignant Syndrome // JAPI. − 2008. − Vol. 56. − P. 49−50.
  • 31. Trollor J.N., Sachdev P.S. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases // Aust NZ J Psychiatry. − 1999. − Vol. 33. − P. 650–659.
  • 32. Malin D.I., Ravilov R.S., Kozyrev V.N. Effektivnost' bromokriptina i dantrolena v kompleksnoi terapii zlokachestvennogo neirolepticheskogo sindroma // Rossiiskii psikhiatricheskii zhurnal. – 2008. – № 5 – S. 75−81.
  • 33. Sakkas P.l., Davis J.M., Janicak P.G., Wang Z.Y. Drug treatment of the neuroleptic malignant syndrome // Psychopharmacol Bull. − 1991. − Vol. 27. − P. 381–384.
  • 34. Dalmau J., Tuzun E., Wu H.Y., Masjuan J. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma // Ann Neurol.− 2007. − Vol. 61. − P. 25–36.
  • 35. Consoli A., Ronen K., An-Gourfinkel I. et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report // Child Adolesc Psychiatry Ment Health. − 2011. − Vol. 5.− P. 15.
  • 36. Kiani R., Lawden, M., Eames P. et al. Anti-NMDA-receptor encephalitis presenting with catatonia and neuroleptic malignant syndrome in patients with intellectual disability and autism // BJ Psych Bulletin. − 2015. − Vol. 39. − P. 32−35.
  • 37. Lancaster E. and Dalmau J. Neuronal autoantigens-pathogenesis,associated disorders and antibody testing // Nature Reviews Neurology. − 2012. − Vol. 8, No. 7. − R. 380–390.
  • 38. Dalmau J., Gleichman A.J., Hughes E. G. et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies // The Lancet Neurology. − 2008. − Vol. 7, No. 12. − R. 1091–1098.
  • 39. Dalmau J., Lancaster E., Martinez-Hernandez, M. R. et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis // The Lancet Neurology. − 2011. − Vol. 10, No. 1. − R. 63–74.
  • 40. Gonzalez-Valcarcel J., Rosenfeld M.R., Dalmau J. Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies // Neurologıa. − 2010. − Vol. 25. − P. 409−413.
  • 41. Steiner J., Walter M., Glanz W. et al. Increased prevalence of diverse N-methyl-Daspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from Nmethyl-D-aspartate glutamate receptor encephalitis // JAMA Psychiatry. − 2013. − Vol. 70. − P. 271–278.
  • 42. Tsutsui K., Kanbayashi T., Tanaka K. et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features // BMC Psychiatry. − 2012. − Vol. 12. − P. 37.
  • 43. Kuppuswamy P.S., Takala C.R., Sola C.L. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions // General Hospital Psychiatry. − 2014. − P. 1−4.
  • 44. Titulaer M.J., McCracken L., Gabilondo I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study // The Lancet Neurology. − 2013. − Vol. 12, No. 2. − P. 157–165.
  • 45. Braakman H.M., Moers-Hornikx V.M., Arts B.M. et al. Pearls and oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis // Neurology. − 2010. − Vol. 75. − P. 44–46.
  • 46. Kruse J.L., Jeffrey J.K., Davis M.C. et al. Anti-N-methyl-Daspartatereceptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management // Ann Clin Psychiatry. − 2014. − Vol. 26. − P. 111–119.
  • 47. Lee A., Glick D., Dinwiddie S. Electroconvulsive therapy in a pediatric patient with malignant catatonia and paraneoplastic limbic encephalitis // J ECT. − 2006 – Vol. 22. − P. 267–270.
  • 48. Lee E.M., Kang J.K., Oh J.S. et al.18F-Fluorodeoxyglucose Positron-Emission Tomography Findings with Anti-N-Methyl-D-Aspartate Receptor Encephalitis that Showed Variable Degrees of Catatonia: Three Cases Report // Journal of Epilepsy Research. − 2014. − Vol. 4, No. 2. − P. 69−73.
  • 49. Matsumoto T, Matsumoto K, Kobayashi T, Kato S. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis // Psychiatry Clin Neurosci. − 2012. − Vol. 66, No. 3. − P. 242–243.
  • 50. Agrawal S., Vincent A., Jacobson L. et al. Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation // Arch Dis Child. − 2009. − Vol. 95. − P. 312.
  • 51. Mirza M.R., Pogoriler J., Paral K. et al. Therapeutic Plasma Exchange For Anti-N-methyl-D-aspartate Receptor Antibody Encephalitis: A Case Report and Review of Literature // Journal of Clinical Apheresis. − 2011. − Vol. 26. − P. 362–365.